NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LimmaTech Biologics

LimmaTech Biologics

Private
SchlierenHealthcare & Life Scienceshttps://lmtbio.com/

Last Round

Grant

Feb 17, 2025

Total Funding Raised

$51.87M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

LimmaTech Biologics is a biopharmaceutical company that specializes in the research, development, and production of innovative bioconjugate vaccines to prevent life-threatening diseases caused by antimicrobial-resistant pathogens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

bioconjugate vaccinesglycoengineeringvaccine developmentinfectious diseasebacterial infectionsbiotechprotein glycosylationantibiotic resistanceclinical-stage biotechdrug discoveryvaccine platformbiopharmasuperbug vaccinesvaccine pipelinenon-dilutive funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LimmaTech Biologics Comps

Public and private peers based on sector, stage, and business model.

LimmaTech Biologics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

LimmaTech Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 17, 2025
GrantFeb 27, 2024
Series A ExtensionFeb 1, 2024
Series AOct 9, 2023
SeedOct 1, 2017

Key People

Founding team and executive leadership

Paul Wolfrom

Co-Founder CFO

Founding Team

Franz-Werner Haas

CEO

Executive Team

LimmaTech Biologics Investors

Notable investors and investment history

LimmaTech Biologics investors
InvestorRounds
CARB-XGrant
AXA IM AltsSeries A Extension, Series A
Novo HoldingsSeries A
BNP Paribas Asset ManagementSeries A
AXA Investment ManagersSeries A
Adjuvant CapitalSeries A Extension, Series A
TenmileSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Monthly visitors grew 74% MoM, reaching 1K.

  • Apr 10, 2025

    Partnering with Valneva to co-develop S4V2 vaccine.

LimmaTech Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LimmaTech Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LimmaTech Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range56
Year Founded2015
Last FundingFeb 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.